Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Coluracetam | Vinpocetine | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 20-80 mg/day divided into 2-3 doses | 5-20 mg 2-3 times daily (15-60 mg/day total) |
| Timing | Morning and early afternoon. Sublingual administration may provide faster onset. With or without food. | With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours). |
| Cycle Duration | Cycles of 4-8 weeks on, 2-4 weeks off | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
Enhances high-affinity choline uptake (HACU) via a unique mechanism distinct from other racetams — it increases HACU even in damaged cholinergic neurons, suggesting a choline uptake enhancement rather than mere stimulation. This HACU enhancement persists even after the compound has been cleared, indicating a lasting modification of choline transporter activity. Also shows affinity for AMPA receptors.
20-80 mg/day divided into 2-3 doses
Morning and early afternoon. Sublingual administration may provide faster onset. With or without food.
Cycles of 4-8 weeks on, 2-4 weeks off
Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.
5-20 mg 2-3 times daily (15-60 mg/day total)
With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →